TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20959284

Group type: EXPERIMENTAL
Intervention: Titrated oxygen treatment
Number of subjects: 405

Group type: COMPARATOR
Intervention: High flow oxygen treatment
Number of subjects: 405
Study: 18238963

Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive (0.75 mg ethinyl estradiol and 6 mg norelgestromin)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (35 mcg ethinyl estradiol and 250 mcg norgestimate)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Transdermal contraceptive
Number of subjects: 24
Study: 16792583

Group type: EXPERIMENTAL
Intervention: drugs + SLIT
Number of subjects: 68

Group type: COMPARATOR
Intervention: drugs + placebo
Number of subjects: 68
Study: 14624409

Group type: EXPERIMENTAL
Intervention: alpha-blockade (prazosin 3 mg/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 11053072

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg twice daily orally for three months
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 18
Study: 8932352

Group type: EXPERIMENTAL
Intervention: Early alternating chemotherapy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Late alternating chemotherapy
Number of subjects: 124
Study: 1434266

Group type: EXPERIMENTAL
Intervention: Adjuvant combination chemotherapy including cis‐platinum
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adjuvant combination chemotherapy including cis‐platinum with 3 or more cycles
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Histologic grade 2 anaplasia
Number of subjects: 50

Group type: COMPARATOR
Intervention: OK‐432 or TJ‐48
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pre‐operative treatment such as irradiation and intra‐arterial chemotherapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (general)
Number of subjects: 50
Study: 3904322

Group type: EXPERIMENTAL
Intervention: Metoprolol-hydralazine treatment
Number of subjects: 161

Group type: COMPARATOR
Intervention: Non-pharmacological management (Control)
Number of subjects: 161
Study: 30808196

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention including five low-moderate intensity 4 km nurse-guided walks, a smartphone application, and a diet workshop
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (counselled on physical activity and healthy diet)
Number of subjects: 204
Study: 29277158

Group type: EXPERIMENTAL
Intervention: Symbiotic treatment (Lactobacillus paracasei, L. rhamnosus, L. acidophilus, Bifidobacterium lactis plus 6 g of fructo‐oligosaccharides)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (placebo: 6 g of maltodextrin)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Symbiotic treatment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 26038091

Group type: EXPERIMENTAL
Intervention: 750 mg intravenous rontalizumab every 4 weeks
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: 300 mg subcutaneous rontalizumab every 2 weeks
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: rontalizumab in ISM-Low patients
Number of subjects: 238

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 238
Study: 24190613

Group type: EXPERIMENTAL
Intervention: 50 mg sildenafil per day for 12 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: 400 IU vitamin E per day
Number of subjects: 39
Study: 22894176

Group type: EXPERIMENTAL
Intervention: Traditional Acupuncture Group (TAG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Acupuncture Group (CAG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Migraine Group (MG)
Number of subjects: 30
Study: 20571436

Group type: EXPERIMENTAL
Intervention: Extra methadone (50% extra dose on top of prescribed daily dosage)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 18607304

Group type: EXPERIMENTAL
Intervention: Training on nasal model (NM) for 15 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: No training on nasal model (NM)
Number of subjects: 20
Study: 16380486

Group type: EXPERIMENTAL
Intervention: Lipid infusion (LIP) with plasma FFA approximately 1,034 micromol/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid infusion (LIP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CON) without lipid infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study: 12760698

Group type: EXPERIMENTAL
Intervention: Dyract Flow (Dentsply DeTrey) with acid etching and/or bonding agent
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delton FS+ (Dentsply International)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Air abrasion alone
Number of subjects: 60
Study: 10790815

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream (Retinova)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Excipient
Number of subjects: 0
Study: 8824695

Group type: EXPERIMENTAL
Intervention: Triazolam 0.375 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Triazolam
Number of subjects: 16
Study: 1429786

Group type: EXPERIMENTAL
Intervention: Marshall‐MacIntosh technique with Kennedy ligament‐augmentation device
Number of subjects: 64

Group type: COMPARATOR
Intervention: Marshall‐MacIntosh technique alone (Control)
Number of subjects: 64
Study: 3841005

Group type: EXPERIMENTAL
Intervention: BRL 20627 (10 mg i.v.)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zetidoline (20 mg orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BK 34/530 (50 mg orally)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BK 34/530 (100 mg orally)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All three drugs
Number of subjects: 0
Study: 30585498

Group type: EXPERIMENTAL
Intervention: Focused extracorporeal shock wave therapy (f‐ESWT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ultrasound therapy (UST)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both f‐ESWT and UST
Number of subjects: 50
Study: 28315812

Group type: EXPERIMENTAL
Intervention: VTE patients
Number of subjects: 83
Study: 25790903

Group type: EXPERIMENTAL
Intervention: UPSA-M
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: UPSA-M Brief
Number of subjects: 34

Group type: COMPARATOR
Intervention: Traditional UPSA scores, UPSA-B scores, and neuropsychological performance
Number of subjects: 34

Group type: COMPARATOR
Intervention: Symptoms of psychopathology, experience with tablet technology, or difficulties operating the device
Number of subjects: 34
Study: 24325052

Group type: EXPERIMENTAL
Intervention: Thread-moxa in Zhuang folk medicine combined with acupuncture and Jingwanhong Scald Ointment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Famciclovir Tablet, nimesulide dispersible tablet, vitamin B1, ribavirin ointment (Control)
Number of subjects: 60
Study: 21506242

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 91

Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 91
Study: 17487211

Group type: EXPERIMENTAL
Intervention: Plant sterol-enriched margarine (2.5 g/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Stanol-enriched margarine (2.5 g/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control margarine (no added plant sterols or stanols)
Number of subjects: 41
Study: 17241586

Group type: EXPERIMENTAL
Intervention: Intralesional injections of bleomycin with electroporation (EP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intralesional injections of bleomycin alone
Number of subjects: 12
Study: 15229960

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 660 mg
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 440 mg
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1200 mg
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 440 mg (subgroup aged > or = 65 years)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Ibuprofen 1200 mg (subgroup aged > or = 65 years)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 440/660 mg
Number of subjects: 444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 444
Study: 11194534

Group type: EXPERIMENTAL
Intervention: Intermittent gastric bolus (IGB)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Continuous gastric infusion (CGI)
Number of subjects: 28
Study: 9113631

Group type: EXPERIMENTAL
Intervention: Dietary Arachidonic Acid (1.7 g/d for 50 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control Diet (210 mg/d of Arachidonic Acid)
Number of subjects: 10
Study: 8471596

Group type: EXPERIMENTAL
Intervention: Adoptive chemoimmunotherapy (ACIT) using autolymphocyte therapy (ALT) and cyclophosphamide
Number of subjects: 21
Study: 3980432

Group type: EXPERIMENTAL
Intervention: Equivalence training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional object-use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Repeated practice trials
Number of subjects: 0
Study: 30921345

Group type: EXPERIMENTAL
Intervention: Picosulfate/magnesium citrate (PMC)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Two-day split dose regimen
Number of subjects: 171

Group type: COMPARATOR
Intervention: One-day split dose regimen
Number of subjects: 171
Study: 29178519

Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26938163

Group type: EXPERIMENTAL
Intervention: Tap water cleansing
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sterile normal saline cleansing
Number of subjects: 22
Study: 24011465

Group type: EXPERIMENTAL
Intervention: PBO (n = 18)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Grinding method (n = 22)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PBO segments with fixation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: PBO segments without fixation
Number of subjects: 40
Study: 22473943

Group type: EXPERIMENTAL
Intervention: Health intervention RCT
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Baseline assessments
Number of subjects: 527
Study: 19840783

Group type: EXPERIMENTAL
Intervention: Citalopram 20mg
Number of subjects: 35
Study: 17684801

Group type: EXPERIMENTAL
Intervention: Atorvastatine treatment for 21 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (basis therapy only)
Number of subjects: 21
Study: 15614200

Group type: EXPERIMENTAL
Intervention: Glucomannan (Chrombalance)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Glucomannan and guar gum (Appe-Trim)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Glucomannan, guar gum and alginate (Glucosahl)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 12166585

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study: 10204900

Group type: EXPERIMENTAL
Intervention: 6 mg morphine diluted in 100 mL 0.9% normal saline (NS) and placebo intramuscular (i.m.) (peripheral MS group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 100 mL of 0.9% NS alone and placebo i.m. (placebo group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 100 mL of 0.9% NS and 6 mg morphine i.m. in the deltoid muscle (i.m. MS group)
Number of subjects: 45
Study: 8657439

Group type: EXPERIMENTAL
Intervention: Regional intravenous guanethidine blockade (RGB)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (tourniquet inflation and i.v. injection of saline)
Number of subjects: 13
Study: 2187006

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (1000 mg twice daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 382151

Group type: EXPERIMENTAL
Intervention: Domperidone (10 mg orally t.d.s. before meals)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31913228

Group type: EXPERIMENTAL
Intervention: TX-001HR (17β-estradiol/progesterone) at various doses (1/100, 0.5/100, 0.5/50, or 0.25/50)
Number of subjects: 1835

Group type: EXPERIMENTAL
Intervention: TX-001HR
Number of subjects: 1835

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1835
Study: 30829213

Group type: EXPERIMENTAL
Intervention: Mukalbion poly herbal chewable tablets
Number of subjects: 70

Group type: COMPARATOR
Intervention: Marketed brand (Poly herbal)
Number of subjects: 70
Study: 29980320

Group type: EXPERIMENTAL
Intervention: 26 Gy boost dose
Number of subjects: 2421

Group type: COMPARATOR
Intervention: 16 Gy boost dose
Number of subjects: 2421
Study: 26574791

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg/day
Number of subjects: 746

Group type: COMPARATOR
Intervention: Glimepiride 8 mg/day
Number of subjects: 746
Study: 25172115

Group type: EXPERIMENTAL
Intervention: Desmopressin (medication used to treat nocturia)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Change in FUSP
Number of subjects: 606
Study: 22809601

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10 mg/kg followed by 5 mg/kg at 24 hours and 48 hours)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (normal saline at 1 mL/kg followed by 0.5 mL/kg at 24 hours and 48 hours)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 19237683

Group type: EXPERIMENTAL
Intervention: Simplified treatment algorithm (initial therapy with low-dose ACE inhibitor/diuretic or ARB/diuretic combination, up-titration to highest dose, addition of calcium channel blocker, addition of non-first-line antihypertensive agent)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Guideline-based management (Canadian Hypertension Education Program guidelines)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Simplified treatment algorithm
Number of subjects: 45
Study: 17573877

Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% cream without occlusion (group I)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% cream with occlusion (group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oxiconazole 1% cream without occlusion (group III)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oxiconazole 1% cream with occlusion (group IV)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall treatment approach
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Follow-up after treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Surgical nail avulsion with topical antifungal agents
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Occlusion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Total dystrophic onychomycosis (TDO)
Number of subjects: 40
Study: 15068402

Group type: EXPERIMENTAL
Intervention: Theophylline (4 mg/kg/day for under 12 years, 3 mg/kg/day for over 12 years)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Methylphenidate (1 mg/kg/day)
Number of subjects: 32
Study: 12050245

Group type: EXPERIMENTAL
Intervention: Supraphysiological recombinant human GH (rhGH; 0.2 IU.kg(‐1).d(‐1))
Number of subjects: 9
Study: 10220796

Group type: COMPARATOR
Intervention: Normal cervical tissue
Number of subjects: 230

Group type: COMPARATOR
Intervention: Low grade SILs
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: High grade SILs
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Well‐differentiated squamous cell carcinomas (WDSCC)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Moderately differentiated squamous cell carcinomas (MDSCC)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Poorly differentiated carcinomas (PDSCC)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: HPV infection
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: E6 protein expression
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: HPV 16-infected lesions
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: E6-expressing cells
Number of subjects: 230
Study: 8541278

Group type: EXPERIMENTAL
Intervention: Fish-oil capsules (2.7 g n‐3 polyunsaturated fatty acids/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Olive-oil capsules (4 g/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 23
Study: 2240638

Group type: EXPERIMENTAL
Intervention: alfentanil/propofol (group P)
Number of subjects: 20

Group type: COMPARATOR
Intervention: alfentanil/midazolam (group M)
Number of subjects: 20
Study: 611326

Group type: EXPERIMENTAL
Intervention: Astrand‐Ryhming Test administered at 50 rpm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Astrand‐Ryhming Test administered at 80 rpm
Number of subjects: 30

Group type: COMPARATOR
Intervention: Maximum oxygen intake determined at the end of a graded exercise test
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison between 50 and 80 rpm Astrand‐Ryhming protocols
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Astrand‐Ryhming Tests at 80 rpm
Number of subjects: 30
Study: 31101538

Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28379802

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 500

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 500
Study: 26558428

Group type: EXPERIMENTAL
Intervention: High-Flux Hemodialysis (HFHD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-Flux Hemodialysis (LFHD)
Number of subjects: 50
Study: 23633277

Group type: EXPERIMENTAL
Intervention: Commercial weight loss program
Number of subjects: 268

Group type: COMPARATOR
Intervention: Primary care intervention
Number of subjects: 268
Study: 21995388

Group type: EXPERIMENTAL
Intervention: MF59-adjuvant vaccine (ATIV)
Number of subjects: 4707

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine without adjuvant (TIV)
Number of subjects: 4707

Group type: COMPARATOR
Intervention: Control (noninfluenza) vaccines
Number of subjects: 4707

Group type: EXPERIMENTAL
Intervention: ATIV vs TIV
Number of subjects: 4707
Study: 19753604

Group type: EXPERIMENTAL
Intervention: Brown diet (BD)
Number of subjects: 18

Group type: COMPARATOR
Intervention: White diet
Number of subjects: 18
Study: 17114599

Group type: EXPERIMENTAL
Intervention: Terbinafine plus aggressive debridement
Number of subjects: 504

Group type: COMPARATOR
Intervention: Terbinafine alone
Number of subjects: 504
Study: 15625793

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural tinnitus coping training (11 sessions)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Habituation-based treatment (5 sessions)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Educational intervention (1 session)
Number of subjects: 77
Study: 14697944

Group type: EXPERIMENTAL
Intervention: CyA, azathioprine, and prednisone
Number of subjects: 45

Group type: COMPARATOR
Intervention: CyA and prednisone
Number of subjects: 45
Study: 11048414

Group type: EXPERIMENTAL
Intervention: Cefazolin administration (1 mg i.v. after ligation of the umbilical cord)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cefazolin administration
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 30
Study: 8530766

Group type: EXPERIMENTAL
Intervention: Early physical abuse
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Biased social information-processing patterns (encoding errors, hostile attributional biases, accessing of aggressive responses, positive evaluations of aggression)
Number of subjects: 584
Study: 2256055

Group type: EXPERIMENTAL
Intervention: l-selenium-methionine (200 micrograms daily)
Number of subjects: 3

Group type: COMPARATOR
Intervention: peaselenium (200 micrograms daily)
Number of subjects: 3

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3
Study: 6170414

Group type: EXPERIMENTAL
Intervention: 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine (AAFC) and 6-thioguanine (TG)
Number of subjects: 51

Group type: COMPARATOR
Intervention: L-6 regimen (control)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: L-12 protocol
Number of subjects: 51

Group type: COMPARATOR
Intervention: L-6 protocol (control)
Number of subjects: 51
Study: 31265338

Group type: EXPERIMENTAL
Intervention: Coaching program consisting of four 90‐minute classes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coaching program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28371937

Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Naldemedine 0.4 mg
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Naldemedine 0.1 mg
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 25426541

Group type: EXPERIMENTAL
Intervention: Protein supplementation (9.3 g of protein/566.4 KJ) plus exercise
Number of subjects: 53

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups (Protein + Exercise and Exercise only)
Number of subjects: 53
Study: 23602843

Group type: EXPERIMENTAL
Intervention: Endoscopic treatment (ET) with dextranomer hyaluronic acid copolymer (Dx/HA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cohen's ureteral reimplantation (UR)
Number of subjects: 41
Study: 21093286

Group type: EXPERIMENTAL
Intervention: Fish oil dietary supplementation, 6 g/day (720 mg of DHA and 1,080 mg of EPA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 19436226

Group type: EXPERIMENTAL
Intervention: 0.25% DHEA (Prasterone) 1.3 mL ovules
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: 0.5% DHEA (Prasterone) 1.3 mL ovules
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: 1.0% DHEA (Prasterone) 1.3 mL ovules
Number of subjects: 218

Group type: COMPARATOR
Intervention: 0% DHEA (placebo)
Number of subjects: 218
Study: 17318503

Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 15540634

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental treatment (NDT) twice a week for 16 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Neurodevelopmental treatment (NDT) five times a week for 16 weeks
Number of subjects: 34